Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Alzheimer's Subject Selection. Subjects who have a clinical diagnosis of mild to moderate Alzheimer's disease will be recruited for this study. The following criteria will be met for inclusion of AD subjects in this study:~  * The participant is 50 years or older.~ * Written informed consent is obtained.~ * Participants have a clinical diagnosis of Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria.~ * Mini-Mental Status Exam score \> 16 and \< 25.~ * Modified Hachinski Ischemia Scale score of ≤ 4.~ * Geriatric Depression Scales (GDS) ≤ 10.~ * For females, non-child bearing potential or negative urine and blood pregnancy test on day of 123-I MNI-340 injection.~* Healthy Control Subject Selection: Healthy control subjects who have no neurological disease will be recruited for this study. The following criteria will be met for inclusion of healthy control subjects in this study:~  * The participant is 50 years or older.~ * Written informed consent is obtained.~ * Negative history of neurological or psychiatric illness based on evaluation by a research physician.~ * Mini-Mental Status Exam score ≥28.~ * For females, non-child bearing potential or negative urine and blood pregnancy test on day of 123-I MNI-340 injection.~Exclusion Criteria:~* Alzheimer's subjects will be excluded from participation for the following reasons:~  * The subject has signs or symptoms of another neurodegenerative disease including Parkinson's disease, diffuse Lewy body dementia, or history of significant cerebrovascular disease.~ * The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness~ * The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery).~ * The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.~ * The subject has participated in another clinical study within the previous 30 days.~ * Clinically significant MRI evidence of vascular disease or alternative neurologic disorder~ * Pregnancy~* Healthy control subjects will be excluded from participation for the following reasons:~  * The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness.~ * The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery).~ * The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.~ * The subject has participated in another clinical study within the previous 30 days.~ * Pregnancy~ * Clinically significant MRI evidence of vascular disease or neurologic disorder

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy